{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~68 mi. (Jena, Germany, +226 more cities)
facility
Universitaetsklinikum Jena ( Site 0305)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~68 mi. (Jena, Germany, +130 more cities)
facility
Universitaetsklinikum Jena ( Site 0252)
drug
BCG solution, +1 more drug
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~68 mi. (Jena, Germany, +158 more cities)
facility
Universitaetsklinikum Jena ( Site 0911)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer
city
~68 mi. (Jena, Germany, +151 more cities)
facility
GSK Investigational Site
drug
niraparib, +1 more drug
drug type
immunotherapy, +1 more type
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
city
~68 mi. (Jena, Germany, +144 more cities)
facility
GSK Investigational Site
drug
carboplatin, +3 more drugs
drug type
chemotherapy, +2 more types
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
city
~68 mi. (Jena, Germany, +156 more cities)
facility
Universitaetsklinikum Jena /ID# 201254
biomarker
IGH-CCND1 Fusion, +1 more biomarker
drug
dexamethasone, +1 more drug
drug type
chemotherapy, +1 more type
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~87 mi. (Erlangen, Germany, +192 more cities)
facility
Universitätsklinikum Erlangen
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~87 mi. (Erlangen, Germany, +207 more cities)
facility
Universitaetsklinikum Erlangen ( Site 1001)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types